MedTrace Logo

Clinical Trials

NCT06172478 | RECRUITING | PHASE2
740 participants

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-10
Start Date:
2024-02-26
Completion:
2027-09-01
Conditions
  • Advanced Solid Tumor
  • Melanoma
  • Head and Neck Cancer
  • Gastric Cancer
  • Ovarian Carcinoma
  • Cervical Cancer
  • Endometrial Cancer
  • Bladder Cancer
  • Esophageal Cancer
  • Pancreatic Carcinoma
  • Prostate Cancer
  • Non-small Cell Lung Cancer (NSCLC)
  • Lung Cancer
  • Breast Cancer
Interventions
  • DRUG
No Results Yet
NCT06105905 | COMPLETED | NA
94 participants

Latino Teen Pregnancy Prevention K23

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-10
Start Date:
2022-09-23
Completion:
2026-06-30
Conditions
  • Pregnancy in Adolescence
  • Rural Health
  • Hispanic or Latino
Interventions
  • BEHAVIORAL
No Results Yet
NCT06092346 | RECRUITING
999 participants

A Natural History Study Seeks to Understand the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders

Study Type:
OBSERVATIONAL
Last Updated:
2026-08-10
Start Date:
2023-12-19
Completion:
2099-01-01
Conditions
  • AMPD3, OMIM*102772, AMP Deaminase Deficiency
  • AK1, OMIM *103000, Adenylate Kinase Deficiency
  • AMPD1, OMIM *102770, Myopathy Due to Myoadenylate Deaminase Deficiency
  • TPMT, OMIM *187680, Thoipurines, Poor Metabolism of
  • IMPDH1, OMIM *146690, Retinitis Pigmentosa Type 10, Leber Congenital Amauriosis Type 11
  • APRT, OMIM *102600, Adenine Phosphoribosyltransferase Deficiency
  • HPRT1, OMIM *308000 Lesch-Nyhan Disease
  • XDH, OMIM *607633, Xanthinuria Type 1
  • SLC2A9, OMIM *606142 Hypouricemia
  • SLC22A12, OMIM *607096 Hypouricemia
  • PRPS1 Def, OMIM *311850, Arts Syndrome; Charcot-Marie-Tooth Disease
  • PRPS1 SA, OMIM *311850 Gout, PRPS-related Phosphoribosylpyrophosphate Synthetase Superactivity
  • AMPD2, OMIM *102771, Spastic Paraplegia 63; Pontocerebellar Hypoplasia
  • ITPA, OMIM *147520, Inosine Triphosphatase Deficiency; Developmental and Epileptic Encephalopathy 35
  • ADSL, OMIM *608222, Adenylosuccinate Lyase Deficiency
  • PNP, OMIM *164050, Nucleoside Phosphorylase Deficiency
  • ADA2, OMIM *607575,Sneddon Syndrome; VAIHS
  • CAD, *1140120, Developmental and Epileptic Encephalopathy
  • UPB1, OMIM *606673, Beta-ureidopropionase Deficiency
  • DPYS, OMIM *613326, Dihydropyrimidinase Deficiency
  • DPYD, OMIM *274270, Dihydropyrimidine Dehydrogenase Deficiency
  • DHODH, OMIM *126064, Miller Syndrome (Postaxial Acrofacial Dysostosis)
  • UMPS, OMIM *613891, Orotic Aciduria
  • NT5C3A<TAB>, OMIM *606224, Anemia, Hemolytic, Due to UMPH1 Deficiency
  • UNG, OMIM *191525, Hyper-IgM Syndrome 5
  • AICDA, OMIM *605257, Immunodeficiency With Hyper-IgM, Type 2; HIGM2
  • Purine-Pyrimidine Metabolism
  • Metabolic Disease
No Results Yet
NCT06046040 | ACTIVE_NOT_RECRUITING | PHASE1
30 participants

TmPSMA-02 in mCRPC

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-10
Start Date:
2024-01-31
Completion:
2027-01-31
Conditions
  • Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Interventions
  • DRUG
No Results Yet
Previous
Sorted by latest updates
Next
Showing 40 trials per page